Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia

Peanut allergy (PA) affects 1% to 2% of individuals in the United States, and significantly impacts quality of life (QoL).1,2 With current management of strict avoidance, the incidence of accidental exposure to peanut is approximately 10% annually, with 30% of exposures requiring epinephrine and medical attention.3,4 In 2020, the U.S. Food and Drug Administration (FDA) approved peanut oral immunotherapy (POIT) with Arachis hypogaea allergen powder (Palforzia, Aimmune, Brisbane, Calif) for the management of PA.